Sanofi

NASDAQ:SNY

Drug Manufacturers - General

Healthcare
$47.12 -0.73%

-$0.31 today

Market cap
$113.15B
Beta
0.28
P/E (TTM)
8.5
EPS (TTM)
$8.60
Dividend yield
5.62%
52W Low $41.86High $52.68

Volume 2.32M

Average 2.78M

SNY EBITDA Margin

EBITDA as a percentage of revenue.

SanofiNASDAQ: SNY

EBITDA Margin · Q2 FY2026 · quarter ended Jun 2026

EBITDA Margin widens to 32.8%

EBITDA Margin was 32.8% in Q2 FY2026, up 2.4 pp from a year earlier. On a trailing-twelve-month basis it was 30.2%, up 0.6 pp year over year. Over 3 fiscal years it narrowed by 6.6 pp.

Context

  • EBITDA Margin widened in 1 of the last 3 fiscal years.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 9 analysts of 36.3% for the fiscal year ending Dec 2026, up from 26.7% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
32.8%+8.7 pp QoQ
Last fiscal yearDec 2025
26.7%+1.8 pp YoY
LTMJun 2026
30.2%+0.6 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+2.4 pp+3.7 pp+1.3 pp
1 year+1.8 pp+9.6 pp+7.8 pp
3 years-6.6 pp+7.6 pp+14.2 pp
5 years+8.5 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
26.7%
Year-over-year change
+1.8pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How SNY compares with its peers on the latest reported figures

  • SNY's LTM Jun 2026 EBITDA Margin of 30.2% is the 7th highest of the 11 companies compared; the peer median is 34.3%.
  • Its year-over-year change of +0.6 pp is the 5th highest of 11, against a peer median of -0.6 pp.
  • Over three fiscal years its change of -6.6 pp compares with a peer median of +7.4 pp.
SNY Competitors Peer median
EBITDA Margin for SNY and competitors
Company Period LTM level YoY 3-year change
NVONovo Nordisk A/SLTM Jun 202654.9% -0.5 pp+7.3 pp
LLYEli Lilly and CompanyLTM Jun 202654.4% +14.4 pp+18.3 pp
AMGNAmgen Inc.LTM Jun 202646.2% +0.7 pp-0.2 pp
NVSNovartis AGLTM Jun 202640.0% -1.1 pp+8.2 pp
AZNAstraZeneca PLCLTM Sep 202634.4% +3.4 pp+13.3 pp
BMYBristol-Myers Squibb CompanyLTM Jun 202634.2% +2.6 pp-10.0 pp
SNYSanofiLTM Jun 202630.2% +0.6 pp-6.6 pp
GSKGSK plcLTM Jun 202626.5% -0.7 pp+2.5 pp
PFEPfizer Inc.LTM Jun 202621.2% -10.4 pp-13.7 pp
MRKMerck & Co., Inc.LTM Jun 202621.0% -18.3 pp+7.6 pp
GILDGilead Sciences, Inc.LTM Jun 20264.4% -33.6 pp+13.7 pp
Peer median (excluding SNY) 34.3%-0.6 pp+7.4 pp

Competitors are the stored peer set for SNY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue39.18B40.56B41.62B44.29B46.72B
Cost of Revenue12.26B11.88B12.63B13.21B13.05B
Gross Profit26.92B28.68B28.99B31.08B33.67B
Gross Margin68.7%70.7%69.7%70.2%72.1%
Research & Development5.69B6.5B6.51B7.39B7.84B
Selling, General & Admin9.56B8.74B8.93B9.18B10.24B
Operating Expenses18.79B18.52B22.03B23.83B24.07B
Depreciation & Amortization3.35B3.11B4.43B3.59B5.68B
EBITDA11.54B13.51B11.39B11.03B12.48B
EBITDA Margin29.5%33.3%27.4%24.9%26.7%
Operating Income8.13B10.16B6.96B7.25B9.6B
Operating Margin20.7%25.1%16.7%16.4%20.5%
Interest Income3.13M168.96M530.5M457.53M331M
Interest Expense377.37M384.8M512.82M622.58M626M
Other Income / Expenses(289M)(170M)(845M)(494M)(3.58B)
Income Before Tax7.84B9.99B6.12B6.76B6.02B
Pre-Tax Margin20.0%24.6%14.7%15.3%12.9%
Income Tax Expense1.56B1.91B1.02B1.2B1.04B
Net Income6.22B8.37B5.4B5.56B7.81B
Net Margin15.9%20.6%13.0%12.6%16.7%
EPS (Basic)2.493.192.152.193.20
EPS (Diluted)2.493.182.152.193.20
Weighted Avg Shares2.51B2.5B2.5B2.5B2.44B
Weighted Avg Shares (Diluted)2.51B2.5B2.51B2.5B2.44B

Sanofi

NASDAQ:SNY

Intrinsic Alpha fair value

Locked

Current Price

$47.12

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.